ArticleCommunications chemistry2026
Synthesis of tetrahydroisoquinoline-fused polycyclic heterocyclic skeletons via Vilsmeier-reagent promoted decarbonylative annulation.
Article in Communications chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The tetrahydroisoquinoline scaffold is an important structural motif in many natural products and pharmaceuticals, known for its broad biological activities. Fused tetrahydroisoquinoline polycyclic heterocyclic structures have increasingly attracted attention, yet their synthetic pathways remain limited. Herein, we developed an efficient, metal-free strategy for assembling tetrahydroisoquinoline-fused polycycles via Vilsmeier-reagent promoted decarbonylative cyclization reaction. The protocol features mild conditions, excellent functional-group tolerance, and high efficiency. Furthermore, biological evaluations demonstrated that the constructed derivatives exhibit antiproliferative activity in cancer cell lines, thereby providing potential starting points for further optimization.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.